Pomaglumetad methionil

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NamePomaglumetad methionil
Drug Alias Name蛋氨珀谷美他LY2140023 monohydratePomaglumetad metionilo美泊谷美特LY 404039 prodrug +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMetabotropic glutamate receptor 2 agonistsMetabotropic glutamate receptor 3 agonists
TargetsMetabotropic glutamate receptor 2Metabotropic glutamate receptor 3
Therapy Area/IndicationsSchizophreniaPsychotic DisordersSubstance-Related Disorders +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUkraine +[28] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDenovo Biopharma LlcEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyDenovo Biopharma Llc
Inactive CompaniesNew York State Psychiatric InstituteUniversity Of California, Los Angeles
Active IndicationsSchizophrenia
Inactive IndicationsPsychotic DisordersSubstance-Related DisordersHepatic Insufficiency

Other Information

ATC CodeN/A
Related LinksDrugBank